Onakpoya I, Spencer E, Heneghan C, Thompson M
Department of Primary Care Health Sciences, University of Oxford, United Kingdom.
Department of Primary Care Health Sciences, University of Oxford, United Kingdom.
Nutr Metab Cardiovasc Dis. 2014 Aug;24(8):823-36. doi: 10.1016/j.numecd.2014.01.016. Epub 2014 Jan 31.
Many different dietary supplements are currently marketed for the management of hypertension, but the evidence for effectiveness is mixed. The aim of this systematic review was to evaluate the evidence for or against the effectiveness of green tea (Camellia sinensis) on blood pressure and lipid parameters.
Electronic searches were conducted in Medline, Embase, Amed, Cinahl and the Cochrane Library to identify relevant human randomized clinical trials (RCTs). Hand searches of bibliographies were also conducted. The reporting quality of included studies was assessed using a checklist adapted from the CONSORT Statement. Two reviewers independently determined eligibility, assessed the reporting quality of the included studies, and extracted the data. As many as 474 citations were identified and 20 RCTs comprising 1536 participants were included. There were variations in the designs of the RCTs. A meta-analysis revealed a significant reduction in systolic blood pressure favouring green tea (MD: -1.94 mmHg; 95% CI: -2.95 to -0.93; I(2) = 8%; p = 0.0002). Similar results were also observed for total cholesterol (MD: -0.13 mmol/l; 95% CI: -0.2 to -0.07; I(2) = 8%; p < 0.0001) and LDL cholesterol (MD: -0.19 mmol/l; 95% CI: -0.3 to -0.09; I(2) = 70%; p = 0.0004). Adverse events included rash, elevated blood pressure, and abdominal discomfort.
Green tea intake results in significant reductions in systolic blood pressure, total cholesterol, and LDL cholesterol. The effect size on systolic blood pressure is small, but the effects on total and LDL cholesterol appear moderate. Longer-term independent clinical trials evaluating the effects of green tea are warranted.
目前有许多不同的膳食补充剂用于高血压管理，但有效性证据不一。本系统评价的目的是评估支持或反对绿茶（茶树）对血压和血脂参数有效性的证据。
在Medline、Embase、Amed、Cinahl和Cochrane图书馆进行电子检索，以识别相关的人类随机临床试验（RCT）。还对手工检索的参考文献进行了检索。使用改编自CONSORT声明的清单评估纳入研究的报告质量。两名评审员独立确定入选标准，评估纳入研究的报告质量，并提取数据。共识别出474篇引文，纳入了20项RCT，涉及1536名参与者。RCT的设计存在差异。荟萃分析显示，绿茶组收缩压显著降低（MD：-1.94 mmHg；95%CI：-2.95至-0.93；I² = 8%；p = 0.0002）。总胆固醇（MD：-0.13 mmol/l；95%CI：-0.2至-0.07；I² = 8%；p < 0.0001）和低密度脂蛋白胆固醇（MD：-0.19 mmol/l；95%CI：-0.3至-0.09；I² = 70%；p = 0.0004）也观察到类似结果。不良事件包括皮疹、血压升高和腹部不适。
摄入绿茶可显著降低收缩压、总胆固醇和低密度脂蛋白胆固醇。对收缩压的效应量较小，但对总胆固醇和低密度脂蛋白胆固醇的效应似乎中等。有必要进行更长期的独立临床试验来评估绿茶的效果。
